7Baggers

We provide you with 20 years of free, institutional-grade data for TNGX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TNGX. Explore the full financial landscape of TNGX stock.

Reported DateTickerType
2026-05-13TNGX10-QUrl
2026-03-05TNGX10-KUrl
2025-11-04TNGX10-QUrl
2025-08-05TNGX10-QUrl
2025-05-12TNGX10-QUrl
2025-02-27TNGX10-KUrl
2024-11-06TNGX10-QUrl
2024-08-07TNGX10-QUrl
2024-05-08TNGX10-QUrl
2024-03-18TNGX10-KUrl
2023-11-08TNGX10-QUrl
2023-08-07TNGX10-QUrl
2023-05-09TNGX10-QUrl
2023-03-27TNGX10-KUrl
2022-11-10TNGX10-QUrl
2022-08-10TNGX10-QUrl
2022-05-11TNGX10-QUrl
2022-03-28TNGX10-KUrl
2021-11-09TNGX10-QUrl
2021-09-10TNGXS-1Url
2021-08-09TNGX10-QUrl
2021-05-14TNGX10-QUrl
2021-03-31TNGX10-KUrl
2020-11-13TNGX10-QUrl
2020-07-30TNGXS-1Url

Tango Therapeutics Inc
(NASDAQ:TNGX) 

TNGX stock logo

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine pho...

Founded: 2017
Founder: Barbara Weber, Alan Ashworth, William Kaelin Jr, Antoni Ribas, José Baselga, and Timothy Lu 
CEO: Barbara Weber  
Sector: REAL ESTATE & CONSTRUCTION
Industry: BLANK CHECKS

Share this website to your friends
The information provided in this report about TNGX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.